

# World Journal of *Immunology*

*World J Immunol* 2011 December 27; 1(1): 1-2





## Editorial Board

2011-2015

The *World Journal of Immunology* Editorial Board consists of 99 members, representing a team of worldwide experts in immunology. They are from 23 countries, including Australia (2), Belgium (1), Canada (5), China (7), France (2), Germany (4), Greece (2), India (6), Ireland (1), Israel (1), Italy (5), Japan (5), Mexico (1), Netherlands (4), Norway (1), Russia (1), Singapore (1), South Korea (6), Spain (4), Sweden (1), Switzerland (1), United Kingdom (6), and United States (32).

### EDITOR-IN-CHIEF

Antonio La Cava, *Los Angeles*  
Seung-Yong Seong, *Seoul*

### GUEST EDITORIAL BOARD MEMBERS

Chih-Hsin Tang, *Taichung*  
Chuen-Mao Yang, *Tao-Yuan*

### MEMBERS OF THE EDITORIAL BOARD



#### Australia

Katherine Kedzierska, *Melbourne*  
Ban-Hock Toh, *Melbourne*



#### Austria

Doris Wilflingseder, *Innsbruck*



#### Belgium

Evelien Smits, *Antwerp*



#### Canada

RM Gorczynski, *Toronto*  
Mladen Korbelik, *Vancouver*  
Rajendra K Sharma, *Saskatoon*  
Pingchang Yang, *Hamilton*  
Zhu-Xu Zhang, *London*



#### China

Xin-Hua Chen, *Xiamen*

Bo Huang, *Wuhan*  
Yan-Jiang Wang, *Chongqing*  
Shi-Cui Zhang, *Qingdao*  
Zhi-Ren Zhang, *Chongqing*



#### France

Armand Bensussan, *Paris*  
Renaudineau Yves, *Brest*



#### Germany

Stephan Immenschuh, *Hannover*  
Dieter Kabelitz, *Kiel*  
Michael Linnebacher, *Rostock*  
Robert Weissert, *Regensburg*



#### Greece

Giorgos T Bamias, *Athens*  
Clio P Mavragani, *Athens*



#### India

Arbind Acharya, *Varanasi*  
Atmaram Hari Bandivdekar, *Mumbai*  
Tapas Biswas, *Kolkata*  
Keya Chaudhuri, *Kolkata*  
Deepak Kaul, *Chandigarh*  
Mohan R Wani, *Pune*



#### Ireland

Anne Fiona McGettrick, *Dublin*



#### Israel

David Naor, *Jerusalem*



#### Italy

Ivano Mezzaroma, *Rome*  
Carlo Perricone, *Rome*  
Alessandro Poggi, *Genoa*  
Francesco Recchia, *Avezzano*  
Carlo Riccardi, *Perugia*



#### Japan

Kenji Kabashima, *Kyoto*  
Osam Mazda, *Kyoto*  
Toshi Nagata, *Hamamatsu*  
Toshimitsu Uede, *Sapporo*  
Hisanori Umehara, *Kahoku-gun*



#### Mexico

Carlos Rosales, *Mexico*



#### Netherlands

Marianne Boes, *Utrecht*  
J Wouter Jukema, *Leiden*  
Frank A Redegeld, *Utrecht*  
Ruurd Torensma, *Nijmegen*



#### Norway

Azzam A Maghazachi, *Oslo*

**Russia**

Georgy A Nevinsky, *Novosibirsk*

**Singapore**

Jeak Ling Ding, *Singapore*

**South Korea**

Sin-Hyeog Im, *Gwangju*  
Mi-Yeon Kim, *Seoul*  
Hyung-Joo Kwon, *Chuncheon Gangwon-do*  
Won-Ha Lee, *Daegu*  
Cheol-Heui Yun, *Seoul*

**Spain**

Joan Claria, *Barcelona*  
Oscar J Cordero, *Santiago de Compostela*  
Victoriano Mulero, *Murcia*  
Annabel F Valledor, *Barcelona*

**Sweden**

Zou Xiang, *Gothenburg*

**Switzerland**

Silvia Monticelli, *Bellinzona*

**United Kingdom**

Rossen Mintchev Donev, *Swansea*  
Eyad Elkord, *Manchester*  
Fang-Ping Huang, *London*  
Dipak P Ramji, *Cardiff*  
Xiao-Qing Wei, *Cardiff*  
Heather M Wilson, *Aberdeen*

**United States**

Hossam M Ashour, *Detroit*  
Paul Ashwood, *Sacramento*  
Sami L Bahna, *Shreveport*

Michael Borchers, *Cincinnati*  
John J Bright, *Indianapolis*  
Stuart K Calderwood, *Boston*  
Christopher Chang, *Philadelphia*  
Arvind Chhabra, *Farmington*  
Lukasz K Chlewicki, *Chicago*  
Yingzi Cong, *Galveston*  
William Cruikshank, *Boston*  
Lauri J Diehl, *South San Francisco*  
D Mark Estes, *Athens*  
Kenneth Adam Frauwirth, *College Park*  
Alasdair M Gilfillan, *Bethesda*  
Azizul Haque, *Charleston*  
Pravin TP Kaumaya, *Columbu*  
Toshiaki Kawakami, *La Jolla*  
Chang H Kim, *West Lafayette*  
Qiao Li, *Michigan*  
Terry Lichtor, *Wilmette*  
Yi Luo, *Iowa City*  
Minggui Pan, *Santa Clara*  
Andras Perl, *Syracuse*  
Rachel L Roper, *Greenville*  
Haval Shirwan, *Louisville*  
Lihua Xiao, *Atlanta*  
Baohui Xu, *Stanford*  
Xiao-Feng Yang, *Philadelphia*  
Thomas Yankee, *Kansas City*  
Song Guo Zheng, *Los Angeles*



# World Journal of Immunology

## Contents

Bimonthly Volume 1 Number 1 December 27, 2011

### EDITORIAL

1

Welcome to the *World Journal of Immunology*

*La Cava A*

## Contents

*World Journal of Immunology*  
Volume 1 Number 1 December 27, 2011

**ACKNOWLEDGMENTS** I Acknowledgments to reviewers of *World Journal of Immunology*

**APPENDIX** I Meetings

I-V Instructions to authors

**ABOUT COVER** La Cava A. Welcome to the *World Journal of Immunology*.

*World J Immunol* 2011; 1(1): 1-2

<http://www.wjgnet.com/2219-2824/full/v1/i1/1.htm>

## AIM AND SCOPE

*World Journal of Immunology* (*World J Immunol*, *WJI*, online ISSN 2219-2824, DOI: 10.5411) is a bimonthly peer-reviewed, online, open-access, journal supported by an editorial board consisting of 99 experts in immunology from 23 countries.

The original articles and reviews in *WJI* cover a wide range of subjects including: (1) autoimmune diseases such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, thyroiditis, myasthenia gravis, in both humans and animal models of disease, with an interest on aspects including the etiology, pathogenesis, mechanisms of disease induction, maintenance and progression; (2) tumor immunology including immunosurveillance, immunoediting and immunotherapies in animal models and in humans; (3) clinical immunology in humans and animal models including mechanisms of disease, regulation and therapy and immunodeficiencies; (4) innate immunity including cell subsets, receptors and soluble mediators, complement and inflammation; (5) adaptive immune mechanisms and cells including soluble mediators and antibodies; (6) immune cell development, differentiation, maturation; (7) control mechanisms for immune cells including immune tolerance and apoptosis; (8) immune cell interactions and immune cell receptors; (9) immunological methods and techniques; (10) immune cell activation including cell signaling pathways, biochemical and pharmacologic modulation studies; (11) infection; (12) different modalities of vaccination including gene therapy; (13) hypersensitivity and allergy; (14) transplantation.

**FLYLEAF** I-III Editorial Board

## EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiao-Cui Yang*

Responsible Electronic Editor: *Xiao-Cui Yang*

Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Xing Wu*

Proofing Editorial Office Director: *Xiao-Cui Yang*

**NAME OF JOURNAL**  
*World Journal of Immunology*

**ISSN**  
ISSN 2219-2824 (online)

**LAUNCH DATE**  
December 27, 2011

**FREQUENCY**  
Bimonthly

**EDITING**  
Editorial Board of *World Journal of Immunology*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381892  
Fax: +86-10-85381893  
E-mail: [wji@wjgnet.com](mailto:wji@wjgnet.com)  
<http://www.wjgnet.com>

**EDITOR-IN-CHIEF**  
Antonio La Cava, MD, PhD, Professor, Depr-

ment of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1670, United States

**Seung-Yong Seong, MD, PhD, Professor**, Department of Microbiology and Immunology, 103 Dachag-no, Jongno-gu, Seoul 110-799, South Korea

**EDITORIAL OFFICE**  
Xiao-Cui Yang, Assistant Director  
*World Journal of Immunology*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381892  
Fax: +86-10-85381893  
E-mail: [wji@wjgnet.com](mailto:wji@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLISHER**  
Baishideng Publishing Group Co., Limited  
Room 1701, 17/F, Henan Building,  
No.90 Jaffe Road, Wanchai, Hong Kong, China  
Fax: +852-31158812  
Telephone: +852-58042046

E-mail: [bpg@baishideng.com](mailto:bpg@baishideng.com)  
<http://www.wjgnet.com>

**PUBLICATION DATE**  
December 27, 2011

**COPYRIGHT**  
© 2011 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

**INSTRUCTIONS TO AUTHORS**  
Full instructions are available online at [http://www.wjgnet.com/2219-2824/g\\_info\\_20100722180909.htm](http://www.wjgnet.com/2219-2824/g_info_20100722180909.htm).

**ONLINE SUBMISSION**  
<http://www.wjgnet.com/2219-2824office/>





## Welcome to the *World Journal of Immunology*

Antonio La Cava

Antonio La Cava, Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1670, United States  
Author contributions: La Cava A solely contributed to this paper.  
Correspondence to: Antonio La Cava, MD, PhD, Professor, Department of Medicine, University of California Los Angeles, 1000 Veteran Avenue 32-59, Los Angeles, CA 90095-1670, United States. [alacava@mednet.ucla.edu](mailto:alacava@mednet.ucla.edu)  
Telephone: +1-310-2674975 Fax: +1-310-2068606  
Received: November 17, 2011 Revised: December 1, 2011  
Accepted: December 20, 2011  
Published online: December 27, 2011



**Figure 1** Editor-in-Chief of the *World Journal of Immunology*. Antonio La Cava, MD, PhD, Professor, Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1670, United States.

### Abstract

We are pleased to announce the launch of the *World Journal of Immunology (WJI)* as a new member of the family of the World series of journals. The pace of discovery in the field of immunology has accelerated significantly in recent years due to important discoveries and the implementation of new technologies and methodologies that have become readily accessible to many investigators. *WJI* is an open-access, peer-reviewed journal, whose preparatory work was initiated on November 30, 2010 and will be officially published on December 27, 2011. The *WJI* Editorial Board consists of 99 experts in experimental medicine from 23 countries. By taking into account the widespread use of the internet and the necessity that scientific journals should reach out to wider audiences through the provision of barrier-free information, *WJI* aims to provide rapid publication through an established system that is targeted at dissemination to the scientific community *via* online open-access.

© 2011 Baishideng. All rights reserved.

**Key words:** Immunology; Journal; Open-access; Peer-reviewed

**Peer reviewer:** Edith Porter, Associate Professor, Department of Biological Sciences, California State University Los Angeles, 5151 State University Drive, Los Angeles, CA 90032, United States

La Cava A. Welcome to the *World Journal of Immunology*. *World J Immunol* 2011; 1(1): 1-2 Available from: URL: <http://www.wjgnet.com/2219-2824/full/v1/i1/1.htm> DOI: <http://dx.doi.org/10.5411/wji.v1.i1.1>

### INTRODUCTION

I am Antonio La Cava, a Professor from the University of California Los Angeles (Figure 1), and together with Seung-Yong Seong, MD, PhD, Professor, Department of Microbiology and Immunology, we will be the co-Editor-in-Chief for *World Journal of Immunology (World J Immunol, WJI)*, online ISSN 2219-2824, DOI: 10.5411. I am very pleased to announce that the first issue of *WJI*, on which preparation was initiated on November 30, 2010, is officially published on December 27, 2011. *WJI* is a bimonthly peer-reviewed, online, open-access, journal supported by an editorial board consisting of 99 experts in immunology from 23 countries. It is my great honor and pleasure to introduce *WJI* as a new forum for both fundamental and clinical immunology. By covering immunological advances in cellular, biochemical and molecular biology; *in vitro* and *in vivo* investigations; basic, translational and clinical immune work, animal models and human studies, *WJI* appears well suited for a broad audience

that has an interest in the multiple subdisciplines of the expanding world of immunology.

Although there are already many journals focusing on immunology, the launch of *WJI* responds to the major technological shift in academic publishing practices during the last decade, that with the internet witnessed an unprecedented revolution in the way science is published and communicated<sup>[1]</sup>. *WJI* aims to extend this aspect to immunologists who want their work published rapidly for access to a broad audience.

*WJI* publishes papers without size limits with a quick editorial turnaround and time-to-publication process, aiming at rapidly reporting results of immunological research through a platform that can facilitate the translation of knowledge into improved human health. To ensure advantages for both authors and readers and the high quality of the published work, submitted manuscripts undergo critical peer review prior to publication.

## CONTENTS FOR PEER REVIEW

In order to guarantee the quality of articles published in the journal, *WJI* usually invites three experts to comment on the submitted papers. The contents for peer review include: (1) whether the contents of the manuscript are of great importance and novelty; (2) whether the experiment is complete and described clearly; (3) whether the discussion and conclusion are justified; (4) whether the citations of references are necessary and reasonable; and (5) whether the presentation and use of tables and figures are correct and complete.

## SCOPE

The original articles and reviews in *WJI* cover a wide range of subjects including: (1) autoimmune diseases such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, thyroiditis, myasthenia gravis, both in humans and in animal models of disease, with an interest on aspects including the etiology, pathogenesis, mechanisms of disease induction, maintenance and progression; (2) tumor immunology including immunosurveillance, immunoediting and immunotherapies in animal models and in humans; (3) clinical immunology in humans and animal models including mechanisms of disease, regulation and therapy and immunodeficiencies; (4) innate immunity including cell subsets, receptors and soluble mediators, complement and inflammation; (5) adaptive immune mechanisms and cells including soluble mediators and antibodies; (6) immune cell development, differentiation, maturation; (7) control mechanisms for immune cells including immune tolerance and apoptosis;

(8) immune cell interactions and immune cell receptors; (9) immunological methods and techniques; (10) immune cell activation including cell signaling pathways, biochemical and pharmacologic modulation studies; (11) infection; (12) different modalities of vaccination including gene therapy; (13) hypersensitivity and allergy; and (14) transplantation.

## COLUMNS

The columns in the issues of *WJI* will include: (1) Editorial: To introduce and comment on the substantial advances and their importance in fast-developing areas; (2) Frontier: To review the most representative achievements and comment on the current research status in important fields, and propose directions for future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (6) Review: To systemically review the most representative progress and unsolved problems in the major scientific disciplines, comment on the current research status, and make suggestions on future work; (7) Original Articles: To report original innovative and valuable findings in immunology; (8) Brief Articles: To briefly report the novel and innovative findings in immunology; (9) Case Report: To report a rare or typical case; (10) Letters to the Editor: To discuss and reply to the contributions published in *WJI*, or to introduce and comment on a controversial issue of general interest; (11) Book Reviews: To introduce and comment on quality monographs of immunology; and (12) Guidelines: To introduce consensus and guidelines reached by international and national academic authorities worldwide on the research in immunology.

In summary, we propose *WJI* as a new forum that can provide answers to important questions on a wide array of topics across multiple immunological disciplines through open access. With our innovative and ambitious publisher, *WJI* will contribute to the swift communication of scientific results in immunology, and contribute to make immunological research more open.

## REFERENCES

- 1 Kaiser J. Scientific publishing. Seeking advice on 'open access,' NIH gets an earful. *Science* 2004; **305**: 764

S- Editor Yang XC L- Editor Webster JR E- Editor Zhang DN



## ACKNOWLEDGMENTS

## Acknowledgments to reviewers of *World Journal of Immunology*

Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of *World Journal of Immunology*. The editors and authors of the articles submitted to the journal are grateful to the following reviewers for evaluating the articles (including those published in this issue and those rejected for this issue) during the last editing time period.

**Antonio La Cava, MD, PhD, Professor,** Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1670, United States

**Edith Porter, Associate Professor,** Department of Biological Sciences, California State University Los Angeles, 5151 State University Drive, Los Angeles, CA 90032, United States

**Seung-Yong Seong, MD, PhD, Professor,** Department of Microbiology and Immunology, 103 Daehag-no, Jongno-gu, Seoul 110-799, South Korea

**Zhu-Xu Zhang, PhD, Assistant Professor,** Department of Medicine, Pathology, University of Western Ontario, UH-B4-231, 339 Windermere Road, London Health Science Center, London, Ontario N6A 5A5, Canada





## Events Calendar 2012

January 8-13, 2012

Keystone Symposia: Chemokines  
and Leukocyte Trafficking in  
Homeostasis and Inflammation  
Colorado, CO, United States

January 16-20, 2012

IFReC-SigN Winter School on  
Advanced Immunology  
Hyogo, Japan

February 5-10, 2012

Keystone Symposia: The Biology of  
Cytokines and the joint meeting on  
Th17 Cells in Health and Disease  
Colorado, CO, United States

March 9, 2012

Cell culture technology: recent  
advances, future prospects  
BioPark Hertfordshire, United  
Kingdom

March 11-16, 2012

Keystone Symposia: Regulation of  
Lymphocyte Signaling  
Colorado, CO, United States

March 14-17, 2012

B22nd Annual Meeting of the  
Society for Virology - Gesellschaft  
für Virologie und Deutsche  
Vereinigung zur Bekämpfung der  
Viruskrankheiten e.V.  
Essen, Germany

March 18-22, 2012

Keystone Symposia: Mutations,  
Malignancy and Memory -  
Antibodies and Immunity  
Massachusetts, CA, United States

March 21-22, 2012

International Symposium: Changing  
the tumor microenvironment: New  
strategies for immunotherapy  
Pamplona, Spain

April 26-27, 2012

Immune Tolerance and  
Autoimmune Disease Conference  
Cambridge, United Kingdom

May 6-11, 2012

International Congress on Adjuvants

and Allergen Vaccines  
Varadero, Cuba

May 9-13, 2012

8th International Congress On  
Autoimmunity  
Granada, Spain

May 20-25, 2012

Keystone Symposia: The Role of  
Inflammation during Carcinogenesis  
Dublin, Ireland

May 23-25, 2012

10th Annual Meeting of  
the Association for Cancer  
Immunotherapy: Towards Next-  
Generation Immunotherapy  
Mainz, Germany

May 31-June 2, 2012

Joint International Congress  
of the American Society for  
Reproductive Immunology and the  
European Society for Reproductive  
Immunology  
Hamburg, Germany

June 1-4, 2012

2012 Frontiers in Immunology  
Research Network International  
Conference  
Salzburg, Austria

June 9-12, 2012

The Neutrophil in Immunity  
Quebec City, Canada

August 18-22, 2012

The 30th World Congress of  
Biomedical Laboratory Science  
Berlin, Germany

September 5-8, 2012

European Congress of Immunology  
Glasgow, United Kingdom

September 22-25, 2012

The EMBO Meeting 2012 -  
Advancing the life sciences  
Nice, France

October 3-6, 2012

15th Biennial Meeting of  
the European Society for  
Immunodeficiencies  
Florence, Italy



## GENERAL INFORMATION

*World Journal of Immunology* (*World J Immunol*, *WJI*, online ISSN 2219-2824, DOI: 10.5411) is a bimonthly peer-reviewed, online, open-access (OA), journal supported by an editorial board consisting of 99 experts in immunology from 23 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e. the maximization of the value to the readers, authors and society.

### Maximization of personal benefits

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of *WJI* and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article via online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since *WJI* is an open-access journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from *WJI* official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair and transparent environment, could contribute their wisdom to edit and publish high-quality articles, thereby realizing the maximization of the personal benefits

of editorial board members, authors and readers, and yielding the greatest social and economic benefits.

### Aims and scope

The original articles and reviews in *WJI* cover a wide range of subjects including: (1) autoimmune diseases such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, thyroiditis, myasthenia gravis, in both humans and animal models of disease, with an interest on aspects including the etiology, pathogenesis, mechanisms of disease induction, maintenance and progression; (2) tumor immunology including immunosurveillance, immunoediting and immunotherapies in animal models and in humans; (3) clinical immunology in humans and animal models including mechanisms of disease, regulation and therapy and immunodeficiencies; (4) innate immunity including cell subsets, receptors and soluble mediators, complement and inflammation; (5) adaptive immune mechanisms and cells including soluble mediators and antibodies; (6) immune cell development, differentiation, maturation; (7) control mechanisms for immune cells including immune tolerance and apoptosis; (8) immune cell interactions and immune cell receptors; (9) immunological methods and techniques; (10) immune cell activation including cell signaling pathways, biochemical and pharmacologic modulation studies; (11) infection; (12) different modalities of vaccination including gene therapy; (13) hypersensitivity and allergy; (14) transplantation.

### Columns

The columns in the issues of *WJI* will include: (1) Editorial: To introduce and comment on the substantial advance and its importance in the fast-developing areas; (2) Frontier: To review the most representative achievements and comment on the current research status in the important fields, and propose directions for the future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (6) Review: To systemically review the most representative progress and unsolved problems in the major scientific disciplines, comment on the current research status, and make suggestions on the future work; (7) Original Articles: To originally report the innovative and valuable findings in experimental medicine; (8) Brief Articles: To briefly report the novel and innovative findings in experimental medicine; (9) Case Report: To report a rare or typical case; (10) Letters to the Editor: To discuss and make reply to the contributions published in *WJI*, or to introduce and comment on a controversial issue of general interest; (11) Book Reviews: To introduce and comment on quality monographs of experimental medicine; and (12) Guidelines: To introduce consensus and guidelines reached by international and national academic authorities worldwide on the research in experimental medicine.

### Name of journal

*World Journal of Immunology*

### ISSN

ISSN 2219-2824 (online)

## Instructions to authors

### Editor-in-Chief

**Antonio La Cava, MD, PhD, Professor,** Department of Medicine, University of California Los Angeles, Los Angeles, CA 90095-1670, United States

**Seung-Yong Seong, MD, PhD, Professor,** Department of Microbiology and Immunology, 103 Dachag-no, Jongno-gu, Seoul 110-799, South Korea

### Editorial Office

*World Journal of Immunology*

Editorial Department: Room 903, Building D,

Ocean International Center,

No. 62 Dongsihuan Zhonglu,

Chaoyang District, Beijing 100025, China

E-mail: [wji@wjgnet.com](mailto:wji@wjgnet.com)

<http://www.wjgnet.com>

Telephone: +86-10-85381892

Fax: +86-10-85381893

### Indexed and Abstracted in

Digital Object Identifier.

### Published by

Baishideng Publishing Group Co., Limited

## SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

### Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics from to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Ridit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJI* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

### Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it

should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

### Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

## SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

### Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/2219-2824office>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS ([http://www.wjgnet.com/2219-2824/g\\_info\\_20100722180909.htm](http://www.wjgnet.com/2219-2824/g_info_20100722180909.htm)) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [wji@wjgnet.com](mailto:wji@wjgnet.com), or by telephone: +86-10-85381891. If you submit

your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

## MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

### Title page

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381892 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJ*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong Uni-

versity, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

### Abstract

There are unstructured abstracts (no more than 256 words) and structured abstracts (no more than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no more than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/...; MATERIALS AND METHODS (no more than 140 words); RESULTS (no more than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g.,  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ; CONCLUSION (no more than 26 words).

### Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

### Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: [http://www.wjgnet.com/2219-2824/g\\_info\\_list.htm](http://www.wjgnet.com/2219-2824/g_info_list.htm).

### Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the printed and E-versions.

### Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

### Notes in tables and illustrations

Data that are not statistically significant should not be noted. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, <sup>c</sup>*P* < 0.05 and <sup>d</sup>*P* < 0.01 are used. A third series of *P* values can be expressed as <sup>e</sup>*P* < 0.05 and <sup>f</sup>*P* < 0.01.



## Instructions to authors

Other notes in tables or under illustrations should be expressed as <sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, etc., in a certain sequence.

### Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[12]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

English journal article (list all authors and include the PMID where applicable)

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

Chinese journal article (list all authors and include the PMID where applicable)

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaobao Zazhi* 1999; **7**: 285-287

In press

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

### Organization as author

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMCID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

### Both personal authors and an organization as author

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

### No author given

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

### Volume with supplement

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

### Issue with no volume

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; (**401**): 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

### No volume or issue

- 9 Outreach: Bringing HIV-positive individuals into care. *HRSA Careaction* 2002; 1-6 [PMID: 12154804]

### Books

#### Personal author(s)

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

#### Chapter in a book (list all authors)

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

#### Author(s) and editor(s)

- 12 **Breedlove GK**, Schorfeide AM. Adolescent pregnancy. 2nd ed. Wiczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

#### Conference proceedings

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

#### Conference paper

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

#### Electronic journal (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

#### Patent (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

### Statistical data

Write as mean  $\pm$  SD or mean  $\pm$  SE.

### Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as  $\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as  $\nu$  (in Greek).



Greek), sample number as *n* (in italics), and probability as *P* (in italics).

### Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h; blood glucose concentration, *c* (glucose)  $6.4 \pm 2.1$  mmol/L; blood CEA mass concentration, *p* (CEA) =  $8.6 \pm 24.5$  µg/L; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: [http://www.wjgnet.com/2219-2824/g\\_info\\_20100725073806.htm](http://www.wjgnet.com/2219-2824/g_info_20100725073806.htm).

### Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

### Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

### Examples for paper writing

**Editorial:** [http://www.wjgnet.com/2219-2824/g\\_info\\_20100725071851.htm](http://www.wjgnet.com/2219-2824/g_info_20100725071851.htm)

**Frontier:** [http://www.wjgnet.com/2219-2824/g\\_info\\_20100725071932.htm](http://www.wjgnet.com/2219-2824/g_info_20100725071932.htm)

**Topic highlight:** [http://www.wjgnet.com/2219-2824/g\\_info\\_20100725072121.htm](http://www.wjgnet.com/2219-2824/g_info_20100725072121.htm)

**Observation:** [http://www.wjgnet.com/2219-2824/g\\_info\\_20100725072232.htm](http://www.wjgnet.com/2219-2824/g_info_20100725072232.htm)

**Guidelines for basic research:** [http://www.wjgnet.com/2219-2824/g\\_info\\_20100725072344.htm](http://www.wjgnet.com/2219-2824/g_info_20100725072344.htm)

**Guidelines for clinical practice:** [http://www.wjgnet.com/2219-2824/g\\_info\\_20100725072543.htm](http://www.wjgnet.com/2219-2824/g_info_20100725072543.htm)

**Review:** [http://www.wjgnet.com/2219-2824/g\\_info\\_20100725072656.htm](http://www.wjgnet.com/2219-2824/g_info_20100725072656.htm)

**Original articles:** [http://www.wjgnet.com/2219-2824/g\\_info\\_20100725072755.htm](http://www.wjgnet.com/2219-2824/g_info_20100725072755.htm)

**Brief articles:** [http://www.wjgnet.com/2219-2824/g\\_info\\_20100725072920.htm](http://www.wjgnet.com/2219-2824/g_info_20100725072920.htm)

**Case report:** [http://www.wjgnet.com/2219-2824/g\\_info\\_20100725073015.htm](http://www.wjgnet.com/2219-2824/g_info_20100725073015.htm)

**Letters to the editor:** [http://www.wjgnet.com/2219-2824/g\\_info\\_20100725073136.htm](http://www.wjgnet.com/2219-2824/g_info_20100725073136.htm)

**Book reviews:** [http://www.wjgnet.com/2219-2824/g\\_info\\_20100725073214.htm](http://www.wjgnet.com/2219-2824/g_info_20100725073214.htm)

5073214.htm

**Guidelines:** [http://www.wjgnet.com/2219-2824/g\\_info\\_20100725073300.htm](http://www.wjgnet.com/2219-2824/g_info_20100725073300.htm)

## SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Please revise your article according to the revision policies of *WJG*. The revised version including manuscript and high-resolution image figures (if any) should be re-submitted online (<http://www.wjgnet.com/2219-2824office/>). The author should send the copyright transfer letter, responses to the reviewers, English language Grade B certificate (for non-native speakers of English) and final manuscript checklist to [wji@wjgnet.com](mailto:wji@wjgnet.com).

### Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

### Copyright assignment form

Please download a Copyright assignment form from [http://www.wjgnet.com/2219-2824/g\\_info\\_20100725073726.htm](http://www.wjgnet.com/2219-2824/g_info_20100725073726.htm).

### Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjgnet.com/2219-2824/g\\_info\\_20100725073445.htm](http://www.wjgnet.com/2219-2824/g_info_20100725073445.htm).

### Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

### Links to documents related to the manuscript

*WJG* will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

### Science news releases

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekAlert/AAAS (<http://www.eurekalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

### Publication fee

*WJG* is an international, peer-reviewed, Open-Access, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. The related standards are as follows. Publication fee: 1300 USD per article. Editorial, topic highlights, original articles, brief articles, book reviews and letters to the editor are published free of charge.